article thumbnail

How to find a drug: the past, present and future of small molecule drug discovery?

DrugBaron

Constructing larger and more diverse screening libraries was, for a while, the competitive advantage of the largest pharma companies. Around the turn of the century, increases in computing capabilities opened up an opportunity to expand the search space by several more orders of magnitude, with the arrival of in silico screening.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

However, the growing volume and complexity of data generated in modern clinical trials present challenges in data capture, storage, analysis, and interpretation4,5. Data quality and management : Ensuring the accuracy, efficiency, integrity, and security of clinical data is key.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharma companies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.

Drugs 98
article thumbnail

Fierce Biotech Week

Fierce BioTech

Fierce Biotech Week Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.

article thumbnail

#Unshackled: The evolving definition of asset-centricity

DrugBaron

These come in many flavours: it could be a technology thread (editing DNA, protein degraders or engineered stem cells for example), deep expertise in a particular indication (“we are the leaders in endometriosis”), or focus on a particular biological mechanism (antigen-presenting cells, mitophagy, caspases or a million other possibilities).

article thumbnail

Zebrafish for Disease Modeling and Drug Screening in Pediatric Cancers

biobide

This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.

Disease 59
article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.